OUTCOME OF BOARD MEETING
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Rekvina Laboratories met on 13 August 2025 and approved the standalone unaudited financial results for Q1 FY26 (quarter ended 30 June 2025). The company reported zero revenue from operations during the quarter, the same as in Q4 FY25 and Q1 FY25. Total expenses stood at ₹3.54 lakhs, comprising ₹2.70 lakhs in employee benefits and ₹0.84 lakhs in other costs. With no income to offset expenses, the company posted a loss before and after tax of ₹3.54 lakhs for the quarter, slightly narrower than the ₹4.28 lakh loss in the previous quarter. The statutory auditors (Y. M. Shah & Co.) issued an unmodified limited review report with no qualifications or emphasis of matter.
Negative — the company continues to generate no operating revenue while incurring costs, leading to persistent quarterly losses. For shareholders, this signals a going-concern risk worth monitoring, as the business currently appears inactive in terms of commercial operations.